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Dietary ﬁber can reduce insulin resistance, body weight, and hyperlipidemia depending
on ﬁber type, water solubility, and viscosity. PolyGlycopleX® (PGX®) is a natural, novel
water soluble, non-starch polysaccharide complex that with water forms a highly viscous
gel compared to other naturally occurring dietary ﬁber.We determined the effect of dietary
PGX® vs. cellulose and inulin on the early development of insulin resistance, body weight,
hyperlipidemia, and glycemia-induced tissue damage in young Zucker diabetic rats (ZDFs) in
fasted and non-fasted states. ZDFs (5 weeks old) were fed a diet containing 5% (wgt/wgt)
cellulose, inulin, or PGX® for 8weeks. Body weight, lipids, insulin, and glucose levels were
determined throughout the study and homeostasis model assessment (HOMA) was used
to measure insulin sensitivity throughout the study in fasted animals. At study termina-
tion, insulin sensitivity (oral glucose tolerance test, OGTT) and kidney, liver, and pancreatic
histopathology were determined. Body weight and food intake were signiﬁcantly reduced
by PGX® vs. inulin and cellulose. Serum insulin in fasted and non-fasted states was signif-
icantly reduced by PGX® as was non-fasted blood glucose. Insulin resistance, measured
as a HOMA score, was signiﬁcantly reduced by PGX® in weeks 5 through 8 as well as ter-
minal OGTT scores in fed and fasted states. Serum total cholesterol was also signiﬁcantly
reduced by PGX®. PGX® signiﬁcantly reduced histological kidney and hepatic damage in
addition to reduced hepatic steatosis and cholestasis. A greater mass of pancreatic β-cells
was found in the PGX® group. PGX® therefore may be a useful dietary additive in the
control of the development of the early development of the metabolic syndrome.
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INTRODUCTION
Dietary ﬁber is generally accepted as having efﬁcacy in disease
states including colorectal cancer, obesity, cardiovascular disease,
insulin resistance, and diabetes (Wilson and Wilson, 1984; Hill,
1997; Howarth et al., 2001; Grunberger et al., 2006; Panahi et al.,
2007). The effects of non-digestible dietary ﬁber are variable
depending on their physicochemical propertieswith viscous,water
soluble ﬁbers being more efﬁcacious for lipid reduction, weight
reduction, and improved glycemic control compared to insoluble,
low viscosity ﬁbers (Blackwood et al., 2000; Jenkins et al., 2000;
Panahi et al., 2007). Improved post-prandial glycemic control and
weight reduction may be due to slowed gastric emptying due to
bulk-forming properties, binding of carbohydrates (Walsh et al.,
1983; Anderson et al., 1999; Chandala et al., 2000), and increased
expression of proglucagon, which is the precursor of glucagon-
like peptide-1 (GLP-1; Reimer and McBurney, 1996; Massimino
et al., 1998; Wang et al., 2007). GLP-1 inhibits gastric emptying,
acid secretion, and glucagon secretion but also increases insulin
sensitivity and secretion (Kim and Egan, 2008). For cholesterol
reduction, viscosity and water solubility are also critical factors
(Venter et al., 1990; Sugatani et al., 2008). High viscosity ﬁbers
interfere with ileal bile acid absorption thereby reducing choles-
terol re-absorption as well as increasing hepatic cholesterolmetab-
olism and breakdown (Judd and Truswell, 1982; Ganji and Kies,
1994). Fibers such as pectin lower hepatic lipid and triglyceride
levels, although these effects are variable, depending on the model
and speciﬁc ﬁber involved (Wilson and Wilson, 1984; Williams,
1991; Anderson et al., 1994).
Levels of non-digestible ﬁber needed to affect critical para-
meters involved with metabolic syndrome vary from 10 to 20 g
per day depending on such factors as viscosity (Rozan et al.,
2008) and efforts to increase viscosity through novel methods of
synthesis may reduce the amount of ﬁber needed to be incor-
porated into food (Rozan et al., 2008). A new ﬁber complex has
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been developed that possesses superior gel-forming properties as
described in detail by Abdelhameed et al. (2010) and Harding
et al. (2010). The viscous polysaccharide used in this study goes
under the name PolyGlycopleX® [(α-d-glucurono-α-d-manno-
β-d-mannoβ-d-gluco), (α-l-glucurono-β-d mannurono), β-d-
gluco-β-d-mannan; PGX®)] (InovoBiologic Inc., Calgary, AB,
Canada) and is manufactured from highly puriﬁed polysaccha-
rides by a proprietary process (EnviroSimplex®) from konjac,
sodium alginate and xanthan gum. These polysaccharides form
a complex with a viscosity higher than any currently known
individual polysaccharide. Although PGX® complex formation
takes place at secondary and tertiary levels (networking and junc-
tion zones), the primary structures of the natural polysaccharides
remain unchanged (Harding et al., 2010) and PGX® is approved
as a Natural Health Product in Canada by Health Canada’s Nat-
ural Health Product Directorate (NHPD) with health claims. A
recently published study showed PGX® to improve acute and
delayed post-prandial glycemic control in healthy human sub-
jects (Brand-Miller et al., 2010) and suggest therapeutic potential
for PGX®, although more detailed studies are necessary. A recent
study by Reimer et al. (2011a) showed signiﬁcant reductions in
body weight and triglycerides in high sucrose fed Sprague-Dawley
rats that were obese but not diabetic but results on these in amodel
of ﬂorid, well developed diabetes in Zucker diabetic rats (ZDFs)
were variable, perhaps due to the degree of damage and the pro-
gression of the disease already present (Grover et al., 2011). In this
model, once diabetes became severe, improvements in glycemic
control were observed. PGX® in the later stages of diabetes actu-
ally preserved body weight, perhaps due to improved glycemic
control and increased efﬁciency of substrates. In addition, PGX®
also increased serum triglycerides in these ZDFs perhaps due to
altered mobilization from the liver. No studies have been done in
young ZDFs to determine the effect PGX® on the development
of metabolic syndrome and this model may be more relevant for
observing effects onbodyweight, triglycerides,and theprogression
of protein glycation-induced tissue damage.
Our goal was to determine the effects of PGX® on food intake,
body weight, glycemic control, and lipids (cholesterol and triglyc-
erides) proﬁle in ZDFs as well as histomorphometric assessment
of liver, pancreas, and kidney damage seen in developing diabetes.
This was done in young ZDFs to assess the ability of this ﬁber to
inhibit or prevent early development of the sequelae of the meta-
bolic syndrome. Inulin in its variant forms improves glycemic
control and reduce body weight (Sugatani et al., 2008), although
usually at doses approximating 10% (Rozan et al., 2008). Our
objective was to determine if PGX® can reduce the development
of aspects of the metabolic syndrome at relatively lower doses.
MATERIALS AND METHODS
EXPERIMENTAL DESIGN
Male ZDFs were used, as they represent a good model of obesity
with co-morbid type 2 diabetes and reduced insulin sensitiv-
ity at the early ages used in the present study (Daubioul et al.,
2002; Lenhard et al., 2004). We used young ZDFs to determine if
PGX® could slow the early progression of obesity and diabetes.
Thirty male ZDF/Crl-Leprfa/fa rats obtained from Charles River,
(Kingston, NY, USA) at 5 weeks of age were housed singly in
suspended wire mesh cages. They conformed to the size recom-
mendations in the most recent Guide for the Care and Use of
Laboratory Animals. All studies were approved by the Euroﬁns
Institutional Animal Use and Care Committee. The animals were
conditioned for 1week after arrival and the animals had access
to water and food ad libitum. At this age, the ZDFs are not
hyperglycemic under fasting conditions, but are insulin resistant,
although glucose is poorly controlled under fed conditions.
PolyGlycopleX®, cellulose, and inulin were shipped to Research
Diets (New Brunswick,NJ,USA) for incorporation into a basic rat
chow (D11725) at 5%wgt/wgt (Table 1). All diets were formulated
to be isoenergetic (PGX® and inulin diets provided 3.98 kcal/g and
cellulose provided 3.90 kcal/g). The ratswere randomly assigned to
one of three groups each given chow containing either: PGX®, cel-
lulose, or inulin (Raftiline®HP) for 8weeks. Cellulose was selected
as the insoluble reference ﬁber that is considered to be inert
(Anderson et al., 1994). Inulin is water soluble and non-digestible
and some papers have shown efﬁcacy for weight reduction, lipid
reduction, and glycemic control, usually at 10%wgt/wgt or greater
(Rozan et al., 2008). An sample size of 10 was used for each group
and no animals were excluded from the study.
Basic monitoring procedures were conducted throughout the
study (i.e., thrice weekly measurement of food intake and once
per week measurement of body weight). Blood glucose and serum
insulin were measured after 16 h fasting once per week and the
blood was collected from the retro-orbital plexus under light
isoﬂurane anesthesia and the ﬁrst measurements were done at the
end of week 1 and then throughout the rest of the study. Measure-
ments while in the fed state are important as this is when hyper-
glycemia is ﬁrst evident and because the action of the ﬁbers are
exerted primarily while they are in the gut, particularly since ZDFs
eat continuously through the night. Measurement of non-fasted
glucose was also done weekly starting at week 3 and throughout
the rest of the study and the measurement of fasted vs. non-fasted
glucose levels were separated by 2 days. We recognized within the
Table 1 | Composition of the three diets containing either PGX®,
cellulose, or inulin*.
PGX® fiber Insoluble fiber Soluble, non-
viscous fiber
Research diets formula # D08012504 D08012507 D08012503
Casein 20% 20% 20%
Methionine 0.3% 0.3% 0.3%
Corn starch 50% 50% 50%
Maltodextrin 15% 15% 15%
Fiber** 5% PGX® 5% cellulose 5% Inulin
Corn oil 5% 5% 5%
Salt/mineral mix 3.5% 3.5% 3.5%
Vitamin mix 1% 1% 1%
Choline bitartrate 0.2% 0.2% 0.2%
Dye 0.1% 0.1% 0.1%
*Percent contribution of ingredients by weight.
**Supplied as PolyGlycopleX® (PGX®; InovoBiologic Inc., Calgary, AB, Canada),
Cellulose (Research Diets, New Brunswick, NJ, USA), and Raftiline® HP (Orafti,
Tienen, Belgium) respectively.
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ﬁrst 2 weeks that non-fasted glucose values would be better predic-
tors of glycemic control given that these animals feed continuously.
Hyperglycemia was only observed in the non-fasted state and this
was also when PGX® was in the gastrointestinal tract. In the non-
fasted state, serum insulin was only measured at the end of the
study [baselinemeasurement of ﬁnal non-fasted oral glucose toler-
ance test (OGTT), see below]. Weekly insulin measurements were
not done in the non-fasted state as too much blood would need to
be withdrawn per week to do this for both fasted and non-fasted
states. We felt that since blood glucose was not elevated in these
young ZDFs when fasted, insulin was the critical variable under
these conditions and consequently we measured this more thor-
oughly. Blood glucose was measured using a Bayer Ascensia Elite
Glucometer (Bayer Health Care, Tarrytown, NY, USA) and serum
insulin was measured using an ELISA (AniLytics, Gaithersburg,
MD, USA). In fasted animals, serum triglycerides were measured
once weekly (along with the glucose measurement) throughout
the study, while in non-fasted animals, only a terminal measure-
ment was taken along with cholesterol (IDEXX, North Grafton,
MA, USA).
The study was concluded with two OGTTs; fasted and non-
fasted with the fasted measurement being done at week 7, the
non-fasted OGTT being done at the end of week 8 and glucose
and insulin were measured after glucose challenge in both groups.
Homeostasis model assessment (HOMA) scores were calculated
throughout the study as (mg glucose×U insulin/mL2) for fasted
animals and at the end of the study for non-fasted animals (base-
line insulin only measured at end of study). Lower HOMA scores
are reﬂective of increased peripheral insulin sensitivity. We also
calculated the composite insulin sensitivity index (CISI) scores for
the OGTT studies using the following formula:
CISI = 1000√
(Glucbase × Insbase) × (Glucmean × Insmean)
.
This score takes into account glucose excursion/area under the
curve (higher score shows improved insulin sensitivity). The ini-
tial (pre-glucose loading) blood sample for the ﬁnal (non-fasted)
OGTT and the ﬁnal 8 week blood samples were also used for a clin-
ical chemistry panel including: electrolytes, blood urea nitrogen
(BUN), blood glucose, creatinine alkaline phosphatase, aspar-
tate aminotransferase (ALT), alanine aminotransferase (AST),
and bilirubin (direct+ indirect), non-fasted insulin and serum
cholesterol (IDEXX, North Grafton, MA, USA).
Oral glucose tolerance tests were performed using an oral 2 g/kg
glucose challenge and blood samples from tail nicks were taken at
30, 60, 90, and 120min after the glucose challenge and were ana-
lyzed for blood glucose and serum insulin content for both fasted
(7weeks) and non-fasted (8weeks) animals. At the conclusion
of the second OGTT, all rats were sacriﬁced by isoﬂurane over-
dose and the relevant organs were harvested for histopathological
analysis.
NECROPSY
One lobe of the liver, one kidney and the pancreas were ﬁxed
in 10% neutral buffered formalin. The pancreas was transferred
to 70% ethanol after 24 h. Tissues were processed and embed-
ded in parafﬁn. The liver and kidney were sectioned (5μm) and
stained with hematoxylin and eosin (H&E). The pancreas was
serial sectioned twice (5μm) and were stained with H&E or
immunohistochemically stained with a mouse antibody against
rat insulin (1:300, Cell Signaling Technology, Danvers, MA, USA).
Immunohistochemistry was performed according to the follow-
ing procedure. Following deparafﬁnization, antigen retrieval was
performed using Declere® solution (Cell Marque™ Corporation,
Rocklin,CA,USA). Slides were incubated for 20min in 5%normal
goat serum. The slides were incubated with the primary antibody
for 60min followed by 30min incubation in biotinylated goat
anti-rabbit and hematoxylin counterstaining. Following necropsy,
an additional liver lobe was snap-frozen, embedded in OCT, sec-
tioned at 5μm, and stained with Sudan black for analysis of lipid
content.
All slides stained with H&E or Sudan black were evaluated for
morphological changes related to those commonly observed in
ZDFs and were graded semi-quantitatively on a scale of 0–5 based
upon the severity of that ﬁnding. The percent of the islet area
with insulin positive cells was measured morphometrically on the
pancreas slides stained with anti-insulin antibody. The percent of
islet area positive for insulin was calculated using ImagePro® Plus
imaging software. Previous work suggests that increased GLP-1
will increase or preserve the density of pancreatic insulin-secreting
cells, although this has not been looked at in detail for dietary ﬁber
(Kim et al., 2007). Circulating GLP-1 is signiﬁcantly increased by
dietary ﬁber (Reimer and McBurney, 1996) and preliminary data
show PGX® to have similar effects (Grover et al., 2011).
STATISTICAL METHODS
Data collected at multiple times were analyzed by two-way
repeated measures analysis of variance (ANOVA) and post hoc
comparisons using Bonferroni’s multiple comparison test (MCT).
Insulin, cholesterol, and blood chemistries measured only at the
end of the study in non-fasted rats were analyzed by one-way
ANOVA followed by post hoc comparisons using Dunnett’s MCT.
Non-interval data (e.g., histology scores) were analyzed by Kruskal
Wallis test and Dunn’s MCT. Signiﬁcance was set at p < 0.05.
RESULTS
FOOD CONSUMPTION AND BODY WEIGHT
Rats fed a PGX®-containing diet gained weight at a signiﬁcantly
slower rate than rats fed cellulose- or inulin-containing diets
(Figure 1A). Food intake was signiﬁcantly lower for PGX®-treated
animals compared to the inulin and cellulose groups up to 4weeks
into the protocol (Figure 1B). Food intake in the PGX® group
remained lower for the rest of the protocol but is not statistically
different from the other two groups although the reduction is still
likely to be physiologically signiﬁcant. A previous study from our
laboratory showed that PGX® increased body weight relative to
control, but this was after the animals were ﬂoridly diabetic and
their bodyweight growth curves were asymptotic. The obese ZDFs
stopped gaining weight much sooner than non-obese rats with the
same genetic background (Grover et al., 2011). This suggests the
possibility that at the late stage of diabetes, body weight may be
difﬁcult to maintain and PGX® helped maintain weight by more
efﬁcient use of substrates.
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GLYCEMIC CONTROL
Under fasted conditions (16 h), rats had near normal (i.e., non-
diabetic) blood glucose concentrations (Figure 2A). Under these
conditions, rats fed the PGX®-containing diet maintained lower
serum insulin concentrations compared to the other groups,which
had elevated insulin (Figure 2B). Signiﬁcant insulin reductions
caused by PGX® were seen starting at week 5 up to study ter-
mination. Insulin resistance during the course of this study in
fasted rats was assessed by calculating HOMA and CISI scores
(Figure 2C; Table 2). HOMA scores rose over the course of the
study but signiﬁcantly less so for the PGX® group from 5 to
8weeks. CISI scores were calculated for the OGTT in fasted ani-
mals (7 weeks) as another test for insulin sensitivity. This score was
signiﬁcantly higher for PGX® treated animals, further showing
improved insulin sensitivity (Table 2).
Under non-fasted conditions, PGX® treated rats had lower
blood glucose compared to rats in the other two groups from
week 3 onwards and signiﬁcantly from weeks 5 through 8
(Figure 2D). In fed animals we only measured serum insulin
under resting conditions before glucose challenge as the baseline
level for the OGTT done at 8 weeks and observed signiﬁcantly
lower insulin in PGX®-fed rats (PGX-fed, 8.68± 0.56 ng/mL;
cellulose-fed; 10.23± 0.52 ng/mL; inulin-fed, 10.91± 0.96 ng/mL;
p < 0.05). Insulin resistance (HOMA) was signiﬁcantly lower in
the PGX® group compared to the other groups (Table 2). The
CISI scores for fed animals are also shown on Table 2 and PGX®
rats showed signiﬁcantly greater insulin sensitivity compared to
the other groups. Glucose levels at 30min post-glucose challenge
FIGURE 1 |The effect of PGX®, cellulose, or inulin diets on body weight
(A) and food consumption (B) in Zucker diabetic rats (ZDFs).The
increase in body weight with respect to time was signiﬁcantly obtunded in
the PGX®-treated animals (cellulose-fed vs. PGX®fed animals, from week 1
to 8). Food consumption was signiﬁcantly reduced in PGX®-treated animals
for the ﬁrst 3–4weeks but the trend continued throughout the study. p
Values marked on the ﬁgure are those of PGX® vs. cellulose.
were signiﬁcantly lower for the PGX® group (Figure 3). As can be
seen from Figure 3, the early part of the glucose response curve
was obtunded by PGX®. After peak glucose concentrations, serum
FIGURE 2 |The effect of PGX®, cellulose, or inulin diets on fasted blood
glucose (A), fasted serum insulin (B), fasted HOMA scores (C), and
non-fasted glucose (D) with respect to time in Zucker diabetic rats
(ZDFs). Fasted blood glucose values were not greatly elevated in any
group. Fasted serum insulin was reduced throughout the protocol by PGX®,
but signiﬁcance was seen starting at 5weeks. Fasted HOMA scores
throughout the study are shown on (C). PGX® signiﬁcantly reduced the
HOMA score starting at 5weeks into the procedure. Non-fasted glucose
(D) was signiﬁcantly reduced by PGX® starting at 5weeks. p Values marked
on the ﬁgure are those of PGX® vs. cellulose.
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Table 2 | Insulin sensitivity measurements* at study termination using
CISI** and HOMA*** scores.
CISI score** PGX® Cellulose Inulin
Fasted 1.4±0.1 0.8±0.1* 0.9±0.1*
Fed 1.1±0.1 0.5±0.1* 0.6±0.1*
HOMA score***
Fed 100.7±9.8 300.0±31.0* 274.5±32.7*
*Signiﬁcantly different from PGX® group (p<0.05).
** CISI = 1000√
(Glucbase×Insbase)×(Glucmean×Insmean )
***HOMA score=mg glucose X U insulin/mL2 (shown for non-fasted animals at
end of study).
The higher the HOMA scores, the greater the insulin resistance. The higher the
CISI scores (taken during fasted OGTT), the greater the insulin sensitivity.
glucose levels did not return to baseline within the 120-min mea-
surement period. This slow return to baseline has been previously
reported for ZDF rats (Han et al., 2008) and high fat and high
carbohydrate-fed mice under similar conditions (Pederson et al.,
1998; Gault et al., 2007) and is likely due to the poor insulin
response seen in these animals as well as being in the fed state.
The non-fasted OGTT was shown as it was felt to be more rel-
evant for the PGX® study. Insulin areas under the curve (AUC)
were not signiﬁcantly different between groups and remained at
higher levels consistent with the elevated glucose but it is possible
that insulin responses were limited in the fed state. Imbedded into
Figure 3, the insulinAUC is shown and PGXonly tended to reduce
the insulin AUC. The CISI score incorporated both glucose and
insulin data and showed increased insulin sensitivity for PGX.
LIPID PROFILE
Serum triglycerides were measured in fasted (throughout study,
Figure 4) and non-fasted states, which were measured only at
the end of the study in order to reduce excess blood withdrawal
(Table 3). In the fasted animals, the results were inconclusive with
PGX® showing an early and signiﬁcant lowering effect on triglyc-
erides. However, after 2–3weeks, this effect was lost. In non-fasted
rats at study end, serum triglycerides were similar and higher for
PGX®- and inulin-treated groupswhile the cellulose-treated group
levels were signiﬁcantly lower than the other two groups (Table 3).
At the end of the study, serum cholesterol was measured in the
baseline sample before the last OGTT (fed state) or as the last
sample for the fasted animals. As seen in Table 3, the animals were
hypercholesterolemic and PGX® signiﬁcantly reduced cholesterol
levels compared to cellulose and inulin-fed groups.
HISTOPATHOLOGICAL EVALUATION OF LIVER, PANCREAS, AND
KIDNEYS
Kidney
Several renal pathology parameters showed differences between
rats fed PGX®-containing diet vs. the other two groups. This was
assessed because of nephropathy commonly seen even in early
diabetes due to protein glycation (Nonaka et al., 2007; Table 4).
The overall degree of renal pathology was mild and is most likely
related to the early phase in the pathogenesis of the diabetes in
the relatively young ZDFs used in this study. Micrographs were
FIGURE 3 | Effects of PGX®, cellulose, or inulin diets on oral glucose
excursion in non-fasted animals after administration of 2g/kg oral
glucose (oral glucose tolerance test; OGTT at 8weeks). PGX®
signiﬁcantly reduced early and peak glucose response to the challenge [(A),
main ﬁgure; *p <0.05] compared to the other ﬁbers. The glucose did not
return to baseline for any group within the time in which blood glucose was
measured for this part of the study. Also shown is the area under the curve
(AUC) for the insulin response [(A), inset]. While there were no signiﬁcant
differences, PGX tended to reduce insulin AUC.When a CISI score was
determined, taking into account, glucose and insulin excursion (B), PGX
signiﬁcantly increased insulin sensitivity. p Values marked on the ﬁgure are
those of PGX® vs. cellulose.
FIGURE 4 | Fasted serum triglycerides for all groups measured
throughout the study.While PGX® showed an early reduction in
triglycerides, the data became variable and therefore hard to interpret. At
the end of the study, inulin and PGX® did signiﬁcantly increase triglycerides
relative to cellulose, butthe mechanism(s) for these changes are presently
unknown. p Values marked on the ﬁgure are those of PGX® vs. cellulose.
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not shown because the differences were subtle and the degree of
damage in the cellulose or reference ﬁber group were so mild as
to be difﬁcult to be seen with the naked eye. Tubule dilatation
was scored absent in PGX® rats, but was found in rats fed inulin
or cellulose and these scores were signiﬁcantly higher in these
groups. Renal tubule degeneration/regeneration scores were sig-
niﬁcantly higher for rats fed cellulose- or inulin-containing diets
compared to PGX®-fed rats. Glomerularmesangial expansion was
reduced in the group receiving PGX®-containing diet with signif-
icant differences noted between the PGX® group vs. inulin-fed
and cellulose-fed rats. Other parameters, including morphologi-
cal changes in the kidneys and clinical chemistries (electrolytes,
creatinine, which are not shown and BUN, Table 3) failed to reach
statistical signiﬁcance. BUN did tend to be lower in the PGX®
treated group and it is likely with further progress of the dis-
ease, this parameter may have eventually reached signiﬁcance. The
kidney damagewas not severe enough to affect some of these para-
meters such as creatinine which is why we chose to examine tissue
histomorphometrically in order to detect the early development
of organ damage.
Pancreas
Rats fed a PGX®-containing diet maintained a signiﬁcantly higher
area of insulin immunoreactivity as a percent of total pancre-
atic islet area compared to rats fed cellulose- or inulin-containing
diets (Table 4; Figure 5) suggesting that PGX® rats can main-
tain a greater reserve capacity for insulin secretion. The remaining
morphological changes in the pancreatic islets showed little or no
treatment effect (data not shown) although scores for islet hem-
orrhage or hemosiderin revealed a trend for lower scores in PGX®
rats. In ZDFs, increased hemorrhage or hemosiderin in islets are
often seen resulting fromdilated blood vessels,particularly inmore
ﬂorid diabetes states (Nugent et al., 2008).
Liver
Rats fed PGX®-containing diet showed less hepatic steatosis than
rats fed cellulose- or inulin-containing diets (Table 4; Figure 6).
Table 3 | Plasma chemistry of key analytes taken at the study
termination in non-fasted rats (baseline measurement of final
non-fasted OGTT).
Diet PGX® Cellulose Inulin
Cholesterol (mg/dL) 179.6±6.4 383.7±23.2* 350.8±21.3*
AST (IU/L) 165.9±24.5 871.4±109.3* 1010.1±169.1*
ALT (IU/L) 93.3±13.3 299.4±30.9* 472.7±77.7**
Bilirubin (mg/dL) 0.1±0.0 0.2±0.0* 0.2±0.0*
Alkaline phosphatase
(IU/L)
134.2±7.7 327.7±46.8* 302.3±30.3*
Globulin (g/L) 3.4±0.1 4.0±0.1* 3.9±0.1*
Albumin (g/dL) 3.1±0.1 2.9±0.1 2.8±0.1
Blood urea nitrogen
(mg/dL)
10.4±0.6 13.4±0.7 15.0±2.6
Triglycerides (mg/dL) 276.4±24.6 276.7±43.5 352.6±67.6**
*Signiﬁcantly different from PGX® group (p<0.05).
**Signiﬁcantly different from cellulose and PGX groups (p<0.05).
Rats fed PGX® diet showed less hepatocyte vacuolation than rats
fed cellulose or inulin (Table 4). Microvesicular hepatocyte vac-
uolation was severe in rats fed a cellulose- or inulin-containing
diet while rats fed a PGX®-containing diet averaged signiﬁcantly
Table 4 | Renal, pancreatic, and hepatic histomorphometric scores at
study termination*.
Diet PGX® Cellulose Inulin
Renal tubule dilation* 0.0±0.0** 1.2±0.3 1.6±21.3
Renal tubule
degeneration/regeneration*
0.1±0.1** 1.1±0.2 1.3±0.2
Renal mesangial expansion* 0.3±0.1** 1.1±0.2 1.3±0.3
Pancreatic insulin–immunoreactive
area (%)*
51.9±2.1** 37.6±2.5 33.4±1.7
Sudan positive hepatocytes* 3.4±0.3** 4.6±0.2 4.1±0.2
Hepatic microvesicular vacuolation* 3.2±0.4** 5.0±0.0 4.6±0.2
Hepatic macrovesicular vacuolation* 1.6±0.2*** 3.1±0.2 2.2±0.2
*Scored morphometrically from 0 to 5.
**Signiﬁcantly different from cellulose and inulin groups (p<0.05).
PolyGlycopleX® signiﬁcantly reduced onset of renal and hepatic pathology
seen with encroaching diabetes and obesity. Percentage of pancreatic insulin–
immunoreactive cells was also increased by PGX® suggesting improved insulin
reserve.
FIGURE 5 | Photomicrograph of the pancreas from PGX® (A), cellulose
(B), and inulin (C) immunohistochemically stained for the presence of
insulin.The pancreas was serial sectioned at 5μm, and slides were
immunohistochemically stained with a mouse antibody against rat insulin.
Sections were evaluated morphometrically for the ratio of insulin to total
islet cell area. PGX® signiﬁcantly increased the morphometrically stained
area composed of insulin-secreting cells compared to cellulose or
inulin-treated groups (p <0.05). The scale bar is 100 microns and images
taken at 10×.
FIGURE 6 | Photomicrograph of livers stained with Sudan black B from
PGX® (A), cellulose (B), and inulin (C) treated animals. Using this stain,
fat appears as blue–black globules. In the PGX® group any fat is present as
very small, rare globules (A). Cellulose (B), and inulin (C) slides contained
signiﬁcantly more lipid globules (p <0.05) and signiﬁcantly more (p <0.05)
microvesicular (arrow) and macrovesicular (arrowhead) globules. Images
taken at 40× magniﬁcation (Bar=50 microns).
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lower scores. In all treatment groups, macrovesicular hepatocyte
vacuolation was less prominent than microvesicular hepatocyte
vacuolation (Table 4). There was a signiﬁcant difference between
groups fed PGX®- vs. cellulose-containing and inulin-containing
diets but no differences were seen between groups fed inulin- and
cellulose-containing diets.
PolyGlycopleX®-treated rats showed signiﬁcantly lower termi-
nal serum ALT levels compared to rats receiving cellulose- or
inulin-containing diets (Table 3). Serum AST showed a similar
pattern (Table 3). Rats fed a PGX®-containing diet had lower
serumalkaline phosphatase levels than rats fed cellulose- or inulin-
containing diets (Table 3). Lower serum alkaline phosphatase
levels caused by PGX® suggests a protective effect on cholestasis,
while decreases in ALT and AST indicate reduced hepatocellular
injury (Pratt and Kaplan, 2001). Conversely, globulin and biliru-
bin are cleared by the liver and elevations reﬂect some degree
of compromised hepatic function. Rats fed a PGX®-containing
diet showed signiﬁcantly lower concentrations of both analytes vs.
Cellulose- and inulin-treated groups, further suggesting improved
liver function (Table 3). The inulin-treated group showed higher
serum levels of hepatic enzymes compared to all other groups,
but it is doubtful if this is meaningful as liver histology showed no
signiﬁcant pathologywhen compared to cellulose-treated animals.
DISCUSSION
Dietary ﬁber is considered to be the edible part of plants or analo-
gous carbohydrates that are resistant to digestion and absorption
in the small intestine but may be subject to partial or complete
fermentation in the colon (Ramberg et al., 2005; Wang et al.,
2007). Cellulose is indigestible as well as being poorly water sol-
uble, and is poorly fermented in the colon. Therefore cellulose is
considered the control, inert ﬁber for dietary ﬁber studies as it is
generally without effects on the parameters tested in the present
study (Anderson et al., 1994). The biological activities of multiple
ﬁber forms are difﬁcult to quantify systematically but have been
variously reported to improve insulin sensitivity, trap nutrients
such as lipids and bile acids and thereby reduce serum cholesterol
and liver lipid content (Judd and Truswell, 1982; Wilson and Wil-
son, 1984; Williams, 1991; Anderson et al., 1994; Ganji and Kies,
1994; Grunberger et al., 2006; Parnell and Reimer, 2010), promote
weight loss in obese subjects (Howarth et al., 2001; Weickert and
Pfeiffer, 2008; Parnell and Reimer, 2009) and improve glycemic
control (Anderson et al., 1999; Panahi et al., 2007; Weickert and
Pfeiffer, 2008; Brand-Miller et al., 2010) in man as well as animals.
Sincewater soluble,high viscosity, gel-formingﬁbers are advan-
tageous for control of lipids, glycemic control, and satiety, some
limited albeit interesting efforts have been made to improve or
optimize the activity of natural ﬁbers with novel chemical enti-
ties (Anderson et al., 1991; Blackwood et al., 2000; Jenkins et al.,
2000; Grunberger et al., 2006; Wang et al., 2007; Abdelhameed
et al., 2010; Harding et al., 2010). We therefore tested a novel ﬁber
complex: PGX®, a highly viscous polysaccharide that imparts a
signiﬁcant increase in the viscosity of gastrointestinal contents at
a lower gravimetric quantity than its ﬁber constituents tested indi-
vidually. This property allows the ﬁber to potentially exert physi-
ological effects at levels lower than other soluble ﬁbers, making it
easier to incorporate into food. PGX® is generally regarded as safe
(Self AfﬁrmedGRAS) with aNOAEL (no observable adverse effect
level) of 50,000 ppm. PGX® showed no toxicity in an OECD 408,
90 day rat (Sprague-Dawley) feeding study (Matulka et al., 2009),
in a genotoxicity study (Marone et al., 2009) or in a controlled
human tolerance trial (Carabin et al., 2009).
The young ZDFs used in this study were in the early stage
of development of diabetes and PGX® reduced the rate of body
weight gain by approximately 10% over the course of the study.
Thismay be partially or wholly due to the reduced food intake seen
during the study or reduced absorption of nutrients (Schneenman,
1985; Ganji and Kies, 1994; Blackwood et al., 2000). PGX® may
have induced satiety either through its volumetric effects in the gut,
slowing of gastric emptying, or by increasing secretion of GLP-1
(Reimer and McBurney, 1996; Massimino et al., 1998;Wang et al.,
2007; Grover et al., 2011). While weight loss has been shown in
various experimental models and clinical trials for several ﬁbers
(Walsh et al., 1983; Schneenman, 1985; Reimer et al., 2011a), not
all studies have shown weight loss for dietary ﬁbers and there
is great variability between ﬁbers (Anderson et al., 1994; Grover
et al., 2011) and this may be model dependent and or related to
the degree of progression of obesity or the metabolic syndrome.
Themanufacture of the highly viscous PGX®was donewith the
idea of optimizing the activity of dietary ﬁber and reducing the
variability of its efﬁcacy. The present study showed clear reduction
of body weight and glycemic control compared to cellulose and
inulin on a wgt/wgt basis. Preliminary studies, just recently com-
pleted, show that the body weight loss in ZDFs caused by PGX®
is associated with a loss of adiposity but also with an increase
in lean mass as measured by dual energy X-ray absorptiometry
(DEXA, unpublished data). The reduced energy intake and asso-
ciated decrease in body fat seen in this study could be related
to alterations in satiety hormone production. This is consistent
with results in man showing increased plasma PYY with PGX®
supplementation (Reimer et al., 2011b). Furthermore, prelimi-
nary, detailed (unpublished) studies in ZDFs in our lab show that
PGX® increases circulating GLP-1 although a less detailed study
also showed a reduction in GLP-1 (Grover et al., 2011). The cur-
rent study represents a broad characterizationof PGX® in a speciﬁc
model of obesity and insulin resistance with developing diabetes
and obesity. Multiple mechanisms for the protective effects of
PGX® will need to be worked out in further studies in order to
explain the improved regulation of glucose homeostasis. It is pos-
sible that these actions of PGX® are secondary to its anti-obesity
effects. While this may be a component, there are studies with
dietary ﬁber that show improvements in glycemic control even
when the animals did not lose weight, so there may be another
component to the action of PGX® that is independent of weight
loss (Yoshida et al., 1991). Studies show that increased levels of
GLP-1 are induced by dietary ﬁber and as stated above, prelimi-
nary evidence as well as published data (Grover et al., 2011) from
our laboratories show that PGX® causes increased GLP-1 levels
which can increase insulin sensitivity as well as act as an insulin
secretagogue. These effects may not be directly related to body
weight loss.
Various dietary ﬁbers show beneﬁcial effects on glycemic con-
trol in animalmodels and inman (Anderson et al., 1999; Chandala
et al., 2000; Jenkins et al., 2000; Panahi et al., 2007; Parnell and
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Reimer, 2009). In our studies, the fasted, young ZDFs did not yet
have greatly elevated glucose levels likely due to the compensation
provided by hyperinsulinemia, showing increased insulin resis-
tance. PGX® probably had no effect on blood glucose in fasted
animals as the ﬁber was not present in the gut under these con-
ditions and the glucose levels in the fasted animals were still
at normal levels making it difﬁcult to reduce glucose further.
Improvements in glucose handling (insulin sensitivity) were seen
with PGX® in both fasted and fed states compared to the other
two diets. In fasted animals, PGX® improved insulin sensitivity as
measured byCISI andHOMAscores.We alsomeasured blood glu-
cose from 3weeks after the initiation of the study through to study
termination in non-fasted animals. While non-fasted animals in
the cellulose and inulin groups were hyperglycemic, glucose lev-
els were reduced or maintained by PGX® to nearly non-diabetic
levels. We only measured resting, fed state insulin at study ter-
mination (the baseline blood sample before the ﬁnal non-fasted
OGTT) and during the OGTT and the signiﬁcantly lower levels
reﬂected improved insulin sensitivity caused by PGX®.
In this study, PGX® prevented the development of insulin resis-
tance in ZDF rats; however, other effects were also observed. PGX®
inhibited the loss of pancreatic β-cell mass, measured as insulin–
immunoreactive area. This suggests that the reserve capacity of the
pancreas is preserved by PGX®. The preservation of two sequential
steps in glucose response shows a high degree of protection from
the early development of diabetes. It is important to note that
the stage of diabetes shown in this study was mild and a reduced
insulin capacity in control-ﬁber treated animals was still not a lim-
iting factor. ZDFs show an increased severity of diabetes with time
and the animals. The results showing a preservation of insulin
reserve (improved pancreatic beta-cell survival) will become crit-
ical as the diabetes becomes more severe. GLP-1 improves both
insulin reserve and sensitivity (Kim and Egan, 2008) and that was
clearly shown in our results. In a much more severe model of
type two diabetes (older ZDFs), insulin levels were increased by
PGX® compared to control animals so GLP-1 not only improved
insulin sensitivity, but also maintained insulin reserve (Grover
et al., 2011). Dietary ﬁbers, including PGX® have been shown
to release GLP-1 as well as preserving pancreatic-β cells (Merani
et al., 2008). While fasted glucose levels were not elevated in this
study, post-prandial glucose (non-fasted) appears to have a greater
predictive value for the onset of early diabetes. Recent data suggest
that post-prandial glucose levels have a higher correlationwith car-
diovascular events than fasting glucose levels (Beisswenger et al.,
2008).
We also determined if PGX® could reduce the appearance of
organ damage secondary to poor glycemic control and perhaps
act to delay or prevent the progression of diabetes. We found
signiﬁcant, albeit modest organ damage present in our animals at
this early stage of diabetes, emphasizing that these changes occur
quickly and fasted glucose may not adequately predict develop-
ing organ damage. Nephropathy is a clinically important sequela
of diabetes, particularly thickening of the glomerular basement
membrane and expansion of the mesangium and tubules. Tubu-
lar degeneration was also seen in these young animals and this
organ damage appeared quickly despite mild diabetes.We showed
less renal injury in the PGX®-fed group, in particular mesangial
expansion.A reduction in protein glycation likely served as amajor
factor in reduced renal injury and shows that fasted glucose levels
by themselves are not perfect predictors of tissue glycation and
further emphasizes the importance of early treatment of type 2
diabetes and insulin resistance.
Serum cholesterol was signiﬁcantly reduced by PGX® and this
is probably related to sequestration of bile acids and subsequent
excretion from the body (Anderson et al., 1999, 1994; Jenkins
et al., 2000). Reduction of cholesterol is probably not secondary to
reductions in weight gain as the mechanism is related to reduced
re-uptake of cholesterol via reduced bile acid absorption. Serum
triglycerides were more variable and therefore the data were dif-
ﬁcult to interpret. Liver steatosis was reduced by PGX® which
may be due to several mechanisms. Reduction of body weight
and mobilization of hepatic fatty acids and triacylglycerides may
have occurred (Daubioul et al., 2002). In another study, Wilson
andWilson (1984) showed increased triglyceride production with
subsequent increases in plasma triglycerides in ZDFs with dietary
ﬁber and thismay explain our data. Therefore, the increased serum
triglyceride levels associated with PGX®may be secondary to body
weight reduction. Reduced liver production and output of glucose
(gluconeogenesis) has been reported for GLP-1 as well as reduced
fatty acid synthesis (Daubioul et al., 2002; Kim and Egan, 2008;
Weickert and Pfeiffer, 2008), so more work needs to be done to
further elucidate PGX®-induced effects on triglycerides. PGX®
reduced indices of hepatocellular injury but also reduced ALT and
AST which is consistent with reduced steatosis and liver damage.
The effect of PGX® on alkaline phosphatase may also indicate
reduced cholestasis.
Obesity and diabetes are on the rise worldwide. Useful treat-
ments for diabetes are still welcomed as both diabetes and obesity
will almost certainly require combination therapies in addition to
diet restriction and a support program. Based on the data in this
report, PGX® may be useful for treatment of diabetes and obesity
andmay be particularly useful for delaying the progression of dia-
betes. Of further signiﬁcance, these studies show that “optimized”
dietary ﬁber combinations such PGX® may show efﬁcacy for dis-
eases such as the metabolic syndrome with much lower amounts
in food than for other soluble ﬁbers.
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